Carregant...
Gemtuzumab Ozogamicin for Treatment of Acute Myeloid Leukemia
INTRODUCTION: Gemtuzumab ozogamicin (GO) is an antibody-drug conjugate consisting of a monoclonal antibody targeting CD33 linked to a cytotoxic derivative of calicheamicin. Despite the known clinical efficacy in relapsed/refractory acute myeloid leukemia (AML), GO was withdrawn from the market in 20...
Guardat en:
| Publicat a: | Expert Rev Clin Pharmacol |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6661897/ https://ncbi.nlm.nih.gov/pubmed/29787320 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/17512433.2018.1478725 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|